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Abstract
Spinal muscular atrophy (SMA), a leading genetic cause of infant death, is caused by the loss of survival motor neuron 1 (SMN1)
gene. SMA is characterized by the degeneration and loss of spinal cord motoneurons (MNs), muscular atrophy, and weakness.
SMN2 is the centromeric duplication of the SMN gene, whose numbers of copies determine the intracellular levels of SMN
protein and define the disease onset and severity. It has been demonstrated that elevating SMN levels can be an important strategy
in treating SMA and can be achieved by several mechanisms, including promotion of protein stability. SMN protein is a direct
target of the calcium-dependent protease calpain and induces its proteolytic cleavage in muscle cells. In this study, we examined
the involvement of calpain in SMN regulation on MNs. In vitro experiments showed that calpain activation induces SMN
cleavage in CD1 and SMA mouse spinal cord MNs. Additionally, calpain 1 knockdown or inhibition increased SMN level
and prevent neurite degeneration in these cells. We examined the effects of calpain inhibition on the phenotype of two severe
SMA mouse models. Treatment with the calpain inhibitor, calpeptin, significantly improved the lifespan and motor function of
these mice. Our observations show that calpain regulates SMN level in MNs and calpeptin administration improves SMA
phenotype demonstrating the potential utility of calpain inhibitors in SMA therapy.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
neuromuscular disorder and the leading genetic cause of infant
mortality [1, 2]. It is characterized by the degeneration of
spinal cord motoneurons (MNs) resulting in muscular atrophy
and weakness [3, 4]. SMA disease is caused by the homozy-
gous disruption of the survival motor neuron 1 (SMN1) gene,
located in chromosome 5q3 (telomeric region), which is re-
sponsible for the production of survival motor neuron (SMN)
protein [5]. In humans, a duplication of the SMN gene (SMN2)
exists in the centromeric region. Most of the transcripts from
SMN2 lack exon 7 and produce a truncated unstable SMN
protein isoform; only 10–20% of SMN2 transcripts are cor-
rectly spliced and produce full-length SMN protein, which is
unable to compensate for SMN1 loss in SMA [6, 7]. Thus, the
number of copies of SMN2 determines intracellular SMN
levels, which in turn define SMA disease onset and severity [8].
Currently available therapies for SMA have demonstrated
that elevating SMN protein ameliorates the disease symptoms
[9]. Several mechanisms increase SMN levels, including SMN2
expression and regulation of SMN protein stability [9–11]. The
mechanisms involved in regulating SMN protein stability in-
clude the ubiquitin proteasome system (UPS) [12, 13], SMN
oligomerization [13], histone deacetylase inhibitors [14], and
autophagy [15, 16]. Some of the SMN stabilizers have been
used to analyze their effect on SMA mice phenotype; recent
results have shown that treatment of severe delta7 SMA mice
with proteasome inhibitors and/or histone deacetylase inhibitors
improves survival and motor function [11, 12, 17].
Calpains are a family of calcium-dependent proteases that
participate in Ca2+-mediated signaling pathways involved in
several cell processes. In humans, the best characterized
calpain isoforms are μ-calpain (calpain 1), predominant in
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the central nervous system, and m-calpain (calpain 2), ubiqui-
tous in all tissues [18]. Increases of cytosolic calcium in neu-
rons activate calpains. Although the physiological roles of
calpain have not yet been fully elucidated, pathological con-
ditions often result in its overactivation. Calpains have been
related to degradation of various cellular proteins in patho-
physiological responses associated with Alzheimer disease,
amyotrophic lateral sclerosis, Huntington disease, Parkinson
disease, spinal cord injury, and ischemia [19–23]. Evidence of
calpain activity in modulating SMN levels in muscle cells [24,
25] led us to explore a potential role of calpain in regulating
SMN stability in MNs. We recently reported that endogenous
reduction of calpain 1 increased autophagy and survival motor
neuron (Smn) protein level in culturedmouse embryonicMNs
[15]. In the present work, we further analyzed the effect of
calpain inhibition on MNs from CD1 and two SMA mouse
models. Our results confirmed our hypothesis that calpain
reduction increases Smn level in cultured mouse MNs.
Calpain 1 knockdown inhibited Smn reduction in culture con-
ditions that increase intracellular calcium level and prevented
neurite degeneration in vitro in Smn-reduced MNs from a
mouse model of severe SMA. To explore the therapeutic po-
tential of calpain inhibition to modify the SMA phenotype, we
administered calpeptin (a calpain inhibitor) to postnatal ani-
mals from two severe SMA mouse models. Calpeptin treat-
ment significantly extended survival and improved motor
function. Our findings suggest that SMN protein can be reg-
ulated by calpain in spinal cord MNs and that calpeptin may
be useful for the treatment of SMA.
Materials and Methods
Spinal Cord MN Isolation and Culture
MN cultures were prepared from embryonic 12.5-day
(E12.5) CD1 or SMA mouse spinal cord essentially as
previously described [26, 27]. Briefly, isolated cells were
pooled in a tube containing culture medium. Isolated MNs
were plated either using 15-mm glass coverslips placed in
four-well tissue culture dishes for immunofluorescence
(15,000 cells/well) or in four-well tissue culture dishes
(Nunc, Thermo Fisher Scientific, Madrid, Spain) for sur-
vival experiments (15,000 cells/well), neurite degenera-
tion evaluation (10,000 cells/well), and western blot anal-
ysis (50,000 cells/well). Wells and glass coverslips were
coated with polyornithine/laminin (Sigma) as described
[28]. Culture medium was Neurobasal medium (Gibco,
Invitrogen, Paisley, UK) supplemented with B27 (2%
v/v, Gibco), horse serum (2% v/v, Fisher Scientific), L-
glutamine (0.5 mM, Gibco), and 2-mercaptoethanol
(25 μM, Sigma) and a cocktail of recombinant neuro-
t rophic fac to rs (NTFs) (1 ng/ml bra in -der ived
neurotrophic factor, 10 ng/ml glial cell line-derived neu-
rotrophic factor, 10 ng/ml ciliary neurotrophic factor,
10 ng/ml cardiotrophin-1, and 10 ng/ml hepatocyte
growth factor; Gibco). Twenty hours after plating,
2 μg/ml of aphidicolin (Sigma) was added to the culture
medium and was maintained throughout the experiment.
SMA Animals
SMA mice FVB·Cg-Tg (SMN2)89AhmbSmn1tm1Msd/J and
F V B . C g - G r m 7 T g ( S M N 2 ) 8 9 A h m b S m n 1 t m 1 M s d
Tg(SMN2*delta7)4299Ahmb/J were kindly provided by Dr.
Josep E Esquerda and Dr. Jordi Caldero (Universitat de
Lleida-IRBLLEIDA). Heterozygous animals were crossed to
obtain homozygous Smn−/−, SMN2+/+ (mutSMA) or Smn−/−,
and SMN2delta7+/+ (SMNdelta7). Littermates mutSMA/
SMNde l t a7 and Smn+ / + , SMN2+ / + /Smn+ / + , and
SMN2delta7+/+ (WT) were used for the experiments. For
MN purification, E12.5 embryos were removed from the uter-
us and a piece was snipped from the head for genotyping; for
in vivo treatment, neonatal offspring were tattooed and a frag-
ment of the tail was collected. The REDExtract-N-Amp
Tissue PCR Kit (Sigma, St Louis, MO, USA) was used for
genomic DNA extraction and PCR setup, with the following
primers: WT forward 5′-CTCCGGGATATTGGGATTG-3′,
SMA reverse 5′-GGTAACGCCAGGGTTTTCC-3′, and WT
reverse 5′-TTTCTTCTGGCTGTGCCTTT-3′.
All procedures were in accordance with the Spanish
Council on Animal Care guidelines and approved by the
University of Lleida Advisory Committee on Animal
Services.
Plasmids and Production of Lentiviral Particles
For RNA interference experiments [26], constructs were gen-
erated in pSUPER.retro.puro (Oligo-Engine, Seattle, WA,
USA) using specific oligonucleotides (Invitrogen) targeting
the calpain 1 (shCalp1) sequence, indicated by capital letters
as follows, forward, gatccccGCGCCAAGCAGGTA
ACTTAttcaagagaTAAGTTACCTGCTTGGCGCttttt, and re-
v e r s e , a g c t a a a a a G C G C C A A G C A G G TA
ACTTAtctcttgaaTAAGTTACCTGCTTGGCGCggg.
pLVTHM, pSPAX2, and pMD2G were kindly provided by
Dr. Trono (University of Geneva, Switzerland). Viruses at
4 × 105–1 × 106 TU/ml were used for the experiments.
Empty vector (EV) was used as a control. For lentiviral trans-
duction, MNs were plated in four-well dishes. Medium con-
taining lentivirus (2 TU/cell) was added 3 h later, and then
changed after 20 h. In each experiment, green fluorescent
protein (GFP)-positive cells were counted directly to monitor
infection efficiency. Frequency of infection rose 99%.
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MN Survival and Neurite Degeneration Analysis
Evaluation of MN survival was performed as described pre-
viously [29]. Cells were plated in complete medium contain-
ing a cocktail of recombinant NTFs or in basal medium with
no supplements or in complete medium containing the exper-
imental conditions. Three days after treatment, large phase-
bright neurons with long neurite processes present in photo-
micrographs of different microscopic areas of tissue-culture
dishes (four central areas per well, three wells for each condi-
tion per experiment) were counted. The number of cells pres-
ent in each dish on day 0 was considered our initial 100%.
Counts were performed every 3 days in the same microscopic
areas as the initial count. Survival was expressed as the per-
centage of cells counted with respect to the initial value
(100%).
Morphometric analysis of neurite degeneration was per-
formed as described [30], with modifications. Briefly, disso-
ciated MNs were cultured as described above and phase-
contrast microscopy images were obtained with a 40× lens
at 6, 9, and 12 days after plating. A grid was created over each
image with NIH ImageJ software [31], using the grid plugin
(line area = 50.000). The cell-counting plugin was used to
score each neurite. Degenerating and healthy cells were count-
ed in at least 10 high-power fields per image (30–50 neurites)
for each well. Three different wells were counted for each
condition (with the observer blinded to the condition) and
the experiments were repeated at least three times. Neurite
segments were considered degenerated if they showed evi-
dence of swelling and/or blebbing.
Calpeptin In Vivo Administration
Mice were individually housed in propylene cages (33 cm ×
18 cm × 14 cm) at an ambient temperature of 22 ± 2 °C and
relative humidity of 40% ± 10%. Breeder mice were provided
with ad libitum water and rodent chow. Mice were maintained
on a 12 h/12 h light/dark cycle (light period 07:30 until 19:30).
mutSMA/SMNdelta7 and WT littermates were assigned ran-
domly to receive treatment or vehicle. Calpeptin (Calbiochem,
Merk, Madrid, Spain) was dissolved in DMSO (50 mM
calpeptin) and injected at a dose of 6 μg per gram of weight
in saline solution. Vehicle groups received equal volumes of
saline solution with the same amount of DMSO.
Administration was via subcutaneous injection (SC,
interscapular region) once a day starting from P0 to death with
a prolypropilene sterile syringe (icogamma plus, 1 mL) and
with a 30G needle (BD Mircolance). WT animals received
treatment or vehicle to a maximum of 3–4 weeks. Birth was
defined as postnatal day 0 (P0) for the experiments. Survival
of animals as well as body mass, size, and behavior test
(righting reflex and tube test) were analyzed.
Behavior Analysis
All tests were conducted during the light period between
09:00 and 12:00 and before the administration. For the
righting reflex test, each pup was turned onto its back on a
flat surface and the time it took to stably place all four paws on
the ground was recorded (cutoff time of 30 s). On the tube test,
animals were placed head down, hanging by the hind limbs in
a plastic 50-ml centrifuge tube with a cotton ball cushion at the
bottom to protect the animal’s head upon its fall. Latency to
fall from the edge of the tube was assessed over a 30-s period
[32]. Three repetitions were performed for each test with a
minimum of 2 min of rest between repetitions. Behavior tests
were performed daily starting at P1 until P10.
Western Blot Analysis
Western blots were performed as previously described [26].
Total cell lysates were resolved in SDS polyacrylamide gels
and transferred onto polyvinylidene difluoride Immobilon-P
transfer membrane filters (Millipore, Billerica, MA, USA)
using an Amersham Biosciences semidry Trans-Blot
(Buckinghamshire, UK). The membranes were blotted with
anti-SMN (Clone 8) antibody (1:5000; BD Biosciences), anti-
SMN1 (2F1) antibody (1:1000; Cell Signaling Technology),
anti-Calpain1 antibody (1:1000; Biomol International Inc.,
Exeter, UK), and anti-Fodrin clone AA6 (1:4000; Biomol).
To control the specific protein content per lane, membranes
were reprobed with monoclonal anti-α-tubulin antibody (1:
50000; Sigma). Blots were developed using Luminata™
ForteWestern HRP Substrate (Millipore).
Immunofluorescence
CulturedMNswere plated on glass coverslips and treatedwith
lentivirus containing EV or shCalp1. Six days after lentiviral
transduction, cells were fixed with 4% paraformaldehyde
(Sigma) for 10 min and with methanol (Sigma) for an addi-
tional 10 min. MNs were permeabilized with 0.2% Triton X-
100 and incubated for 1 h with 5% BSA in PBS. Primary
antibody (SMN antibody, 1:100) was diluted in PBS and in-
cubated overnight. After washing, the secondary antibody
anti-mouse ALEXA555 (Invitrogen) was added at 1:400 dilu-
tion. Hoechst (1:400, Sigma) staining was performed to iden-
tify nuclear localization inMNs soma. Samples were mounted
using Mowiol (Calbiochem) mounting medium. Microscopy
observations were performed in a FV1000 Olympus confocal
microscope (Tokyo, Japan).
Statistical Analysis
All experiments were performed at least three times. Values
were expressed as mean ± SEM. Statistical analyses were
Mol Neurobiol
performed using GraphPad Prism (version 5) (GraphPad
Software Inc.) Differences were assessed by log-rank
Mantel-Cox test for survival comparisons, and by Student t
test or two-way ANOVAwith Bonferroni post hoc test for all
other analysis; P values < 0.05 were considered significant.
Results
Calpain 1 Knockdown Increases Smn Protein Level
in Cultured Spinal Cord MNs
Calpains are involved in several muscle and neurodegenera-
tive disorders, including SMA, and Smn is a direct target of
calpain cleavage in muscle tissue [24, 25]. To analyze the
effect of calpain reduction on Smn in spinal cord MNs, we
used a lentiviral RNA interference method to downregulate
the calpain protein level in these cells. Embryonic (E12.5)
spinal cord MNs were isolated and plated in culture wells.
Three hours later, we transduced them with lentivirus contain-
ing EVor short hairpin RNA sequences targeting specific sites
of mouse calpain 1 (shCalp1) [26] and maintained in the pres-
ence of the neurotrophic factors cocktail (NTFs) (1 ng/ml
brain-derived neurotrophic factor; 10 ng/ml glial cell line-
derived neurotrophic factor, 10 ng/ml ciliary neurotrophic fac-
tor, 10 ng/ml cardiotrophin-1 and 10 ng/ml hepatocyte growth
factor). At 3, 6, and 9 days after transduction, cell lysates were
collected and submitted to western blot using an anti-SMN
antibody. We observed a significantly increased Smn protein
level in shCalp1 cells after 3 (1.30 ± 0.09, p < 0.05), 6 (1.69 ±
0.19, p < 0.005), and 9 (1.75 ± 0.46, p < 0.05) days of trans-
duction, compared with the EV (Fig. 1a). Control blot analysis
using an anti-calpain antibody demonstrated that calpain pro-
tein was reduced in shCalp1 condition compared to EV. To
analyze whether this Smn reduction is preferentially localized
in cell soma or neurites, we measured Smn levels with immu-
nofluorescence using confocal microscopy. MNs were plated
on glass coverslips and transduced using the EV or shCalp1
constructs. Six days after transduction, cells were fixed and
Smn immunostaining with anti-SMN antibody was per-
formed. Using the NIH ImageJ software, quantification of
the average of fluorescence units (AFU) showed that Smn
increases in both MN soma (AFU 115.80 ± 7.27, p < 0.001)
and neurites (AFU 12.29 ± 2.21, p < 0.0005) in shCalp1 cells,
compared to EV (AFU 85.43 ± 5.34 and 6.18 ± 0.56, respec-
tively) (Fig. 1b).
To elucidate the effect of calpain reduction on MNs viabil-
ity, survival experiments were performed. Cells were plated at
low density to avoid cell contact-mediated effects (~ 8000
cells/cm2) and were cultured under several conditions: non-
transduced cells in the absence (NBM) or the presence of
NTFs, and EV- or shCalp1-transduced cells in the presence
of NTFs. At 3, 6, and 9 days after plating, cells were counted
in three wells of each condition. Considering 100% the initial
number of cells present in a well on day 0, survival was esti-
mated as the percentage of remaining cells in the same well.
As shown in Fig. 1c, using the phase-contrast microscope, we
observed that after 9 days without NTFs, MNs were largely
degenerated and had a significantly lower percentage of sur-
viving cells (day 3, NBM 3.38 ± 5.86% vs. NTFs 64.38 ±
3.90%, p < 0.001). However, the presence of EV or shCalp1
did not significantly modify MN survival, compared to the
NTFs condition (day 9, 40.76 ± 2.63%, 44.11 ± 5.12%, and
42.35 ± 2.51%, respectively). Therefore, endogenous calpain
reduction did not reduce MNs viability.
Calpain 1 Knockdown Prevents Smn Reduction
Caused by Membrane Depolarization
Addition of high K+ to the culture medium induces chronic
depolarization of the neuronal plasma membrane, which in
turn activates voltage-gated calcium channels (VGCCs),
resulting in Ca2+ influx and elevation of intracellular Ca2+
concentration [26, 28]. Reaching the appropriate intracellular
Ca2+ level induces the activation of Ca2+-dependent proteases
such as calpains. To elucidate the effect of intracellular Ca2+
increase on Smn level and the mediating role of calpain, we
isolated E12.5 mice spinal cord MNs and established a prima-
ry culture in the presence of NTFs. Cells were transduced with
EV or shCalp1 constructs. Six days later, cells were treated
with 30 mM of KCl (30K) for 3 h and protein extracts were
obtained and submitted to western blot using anti-SMN anti-
body. Smn protein was significantly reduced in 30K EV-
treated cultures (0.5 ± 0.15-fold, p < 0.0001) compared to
non-treated EV control (Fig. 2). As expected, shCalp1 (1.5
± 0.15-fold) treatment induces Smn increase when compared
with EV control (p < 0.005). However, no significant differ-
ences of Smn level were observed in 30K shCalp1, compared
to shCalp1 condition (1.5 ± 0.4- and 1.5 ± 0.15-fold, respec-
tively), suggesting that high K+ treatment induced Smn pro-
tein reduction through calpain activity in cultured spinal cord
MNs.
Calpeptin Treatment Increases Smn Protein Level
in Cultured Spinal Cord MNs
To further assess the role of calpain activity on Smn protein
level in MNs, we used the cell-permeable inhibitor calpeptin
[33]. We first analyzed the effect of calpeptin in basal culture
conditions. E12.5 MNs were isolated and cultured in the pres-
ence of NTFs. Six days later, plating culture medium was
changed to fresh medium containing NTFs or NTFs plus
25 μM calpeptin. Total cell lysates were obtained at 3, 9, 16,
20, and 24 h after treatment and submitted to western blot
protein analysis using an anti-Smn antibody. Smn protein lev-
el was significantly increased after 3, 9, 16, and 20 h of
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calpeptin treatment, compared to non-treated controls (3.34 ±
0.56, p < 0.005; 4.40 ± 0.58, p < 0.005; 2.89 ± 0.61, p < 0.05;
and 2.06 ± 0.50, p < 0.05, respectively; Fig. 3a). No changes
of Smn protein were observed in cells treated 24 h, indicating
that calpain inhibition using calpeptin increases Smn up to
24 h of treatment in culturedMNs. No changes in Smn protein
were observed in cells treated 24 h with calpeptin, indicating
that inhibition of calpain by calpeptin increased Smn up to
24 h of treatment in cultured MNs. This temporary effect
may have been due to the degradation of calpeptin; the pro-
viders recommend that the aqueous solution not be stored for
more than 1 day. Future research should consider the effect of
calpeptin degradation by refreshing the media and/or varying
other experimental conditions.
a b
Fig. 1 Effect of endogenous calpain reduction on Smn protein level and
survival of cultured spinal cord MNs. Mouse MNs were transduced with
lentivirus containing the shCalp1 or empty vector (EV) constructs and
maintained in the presence of neurotrophic factors cocktail (NTFs). a
Protein extracts of 3-, 6-, and 9-day transduced cultures were submitted
to western blot analysis and probed with anti-SMN or anti-calpain anti-
bodies. Membranes were reprobed with an anti-α-tubulin antibody, used
as a loading control. Graph represents the expression of Smn and corre-
sponds to the quantification of at least five independent experiments ±
SEM. Asterisks indicate significant differences using Student t test
(*p < 0.05; **p < 0.005). b Representative confocal images of 6-day
EV- and shCalp1-transduced cells maintained in the presence of NTFs.
Cells were fixed and immunofluorescence was performed with an anti-
Smn antibody (red). Blue indicates Hoechst nuclear staining and green
indicates green fluorescent protein (GFP) expression. Graphs represent
the mean of relative Smn fluorescence (red) measured in soma (left) or
neurites (right) of 6-day transduced cultures, corresponding to the quan-
tification of five independent experiments ± SEM. Scale bar, 5 μm.
Asterisks indicate significant differences using Student t test (SOMA
p < 0.001; NEURITES p < 0.0005). c Representative phase-contrast im-
ages of non-transduced MNs cultured (6 days) in the presence or absence
of NTFs (NBM, NTFs, respectively; top panels), and representative im-
ages of 6-day EV- and shCalp1-transduced cells (bottom panels). Graph
represents the percentage of surviving cells after 3, 6, or 9 days in the
following culture conditions: NBM, NTFs, EV- or shCalp1-transduced
cells. The mean ± SEM corresponds to the quantification of five indepen-
dent experiments. Scale bar, 30 μm
Mol Neurobiol
To study whether calpeptin treatment reverts Smn re-
duction caused by chronic membrane depolarization, pri-
mary CD1 MN cultures were established. Six days after
plating, cells were treated with NTFs (control) or NTFs
plus 30K or 25 μM calpeptin or 25 μM calpeptin+30K.
Three hours after treatment, cell lysates were obtained
and submitted to western blot using anti-α-fodrin or
anti-SMN antibodies. Degradation of α-fodrin to the
150/145 kDa-specific fodrin breakdown products indi-
cates calpain activation [34]. The levels of 150/
145 kDa product in cells treated with NTFs plus 30K
(30K) were significantly increased compared to NTF
control condition (1.33 ± 0.13, p < 0.0001). However,
the addition of calpeptin to NTF control or 30K condi-
tions significantly reduced fodrin cleavage products
(0.66 ± 0.05, p < 0.001, and 0.63 ± 0.07, p < 0.001, re-
spectively) (Fig. 3b). This result suggests that calpain
is activated after membrane depolarization in mouse
MNs. Smn protein level in calpeptin+30K-treated cells
(1.67 ± 0.26, p < 0.05) was significantly increased com-
pared to 30K and control conditions (Fig. 3b). These
results together indicate that Smn is reduced in 30K-
treated cells, and this effect can be prevented by
calpeptin treatment.
High Potassium Treatment Induces Smn Cleavage
in Cultured MNs
In muscle tissue and in U2-OS cell lines, SMN is processed by
calpain leading to the production of N- and C- terminal cleav-
age products [24, 25]. To identify some of these cleavage
products in cultured MNs, we isolated E12.3 MNs from
CD1 mice and cultured for 6 days in the presence of NTFs.
Cells were treated for 3 h with 30 mM KCl (30K) or with
25μM calpeptin or 30K plus 25 μM calpeptin, and total ly-
sates were analyzed by western blot using two monoclonal
antibodies, anti-SMN (Clone 8) (BD Bioscience) and anti-
SMN1 antibody (9F2) (Cell Signaling), to detect the cleavage
products. Anti-SMN antibody (Clone 8) recognizes full-
length and N-terminal fragments, and anti-SMN1 (9F2) anti-
body recognizes C-terminal fragments. Quantification of full-
length Smn (~ 37 kDa) showed that 30K treatment significant-
ly reduced Smn protein level (0.59 ± 0.07, p < 0.0001), where-
as calpeptin treatment increased Smn (2.27 ± 0.50, p < 0.05),
compared to non-treated control. When the same membranes
were overexposed, we detected an increase of N-terminal Smn
cleavage product (~ 20 kDa) in 30K condition (1.98 ± 0.50,
p < 0.05), compared to the untreated control, which was
prevented by addition of 25 μM calpeptin to the medium
(0.53 ± 0.12, p < 0.05) (data not shown).
Using the anti-SMN1 antibody, C-terminal fragments (~
17 kDa) were only evident when the membrane was
overexposed. As shown in Fig. 4, Smn C-terminal fragments
were significantly increased in 30K (1.49 ± 0.29; p < 0.05),
compared to control. Conversely, calpeptin treatment signifi-
cantly reduced C-terminal fragments in 30K and control con-
ditions (0.22 ± 0.04 p < 0.05, and 0.27 ± 0.04, p < 0.0001, re-
spectively). These results together suggest that high K+ treat-
ment reduces full-length Smn and increases C-terminal
fragments.
Calpeptin Treatment Increases Smn Protein Level
and Prevents Neurite Degeneration in SMA Mutant
MNs
To determine whether calpeptin treatment regulates Smn in
MNs from E12.5 embryos of the severe SMA transgenic
mouse model (FVB·Cg-Tg (SMN2)89AhmbSmn1tm1Msd/
J), mice were genotyped and the spinal cords of wild-type
(WT) and mutant (mutSMA) were dissected. WT and
mutSMA isolated MNs were cultured in the presence of
NTFs, carefully following the same protocol used for CD1
cells: six days after plating,WTand mutSMA cells were treat-
ed with 25 μM calpeptin during 3 h. Protein extracts were
collected and submitted to western blot analysis using anti-
SMN antibody. Results indicate that Smn is increased in
calpeptin-treated WT condition (2.13 ± 0.50-fold induction,
p < 0.05) compared to WT control (Fig. 5a, left graph).
Fig. 2 Calpain 1 knockdown prevents Smn reduction caused by
membrane depolarization. Mouse MNs were transduced with lentivirus
containing the shCalp1 or empty vector (EV) constructs and maintained
in the presence of NTFs cocktail. Six days after transduction, cells were
treated using basal medium with (30 K) or without (Control) 30 mMKCl
during 3 h. Protein extracts were submitted to western blot using anti-
SMN or anti-calpain antibodies. Membranes were reprobed with an anti-
α-tubulin antibody. Graph values represent the expression of Smn vs α-
tubulin and correspond to the quantification of three independent exper-
iments ± SEM. Asterisks indicate significant differences using Student t
test (**p < 0.005; ***p < 0.0001)
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Furthermore, in mutSMA cultures, calpeptin treatment in-
creased Smn protein, compared to mutSMA non-treated cells
(5.18 ± 1.48-fold induction, p < 0.05) (Fig. 5a, right graph).
Focal axonal swellings have been previously described in
Smn-reduced mouse tissues and MNs [27, 35]. To determine
the presence of neurite degeneration inMNs obtained from the
severe SMA mouse model (Smn−/−; SMN2+/+), cells were
isolated from the mutSMA and WT mice at E12.5 and cul-
tured at a low density (~ 5000 cells/cm2). We assessed neurite
degeneration by quantifying neurite segments in a determinate
area of the plate using phase-contrast microscopy at days 6, 9,
and 12. Neurites were considered degenerated if they showed
evidence of swellings and/or blebbing (see BMaterials and
Methods^) [30]. Nine and 12 days after plating in the presence
of NTFs, mutSMA MNs showed a higher percentage of de-
generation compared toWTMNs (9 days, WT 15.68 ± 6.67%
of degenerated neurites and mutSMA 30.13 ± 13.10%,
p < 0.05; 12 days, WT 24.10 ± 7.37% and mutSMA 43.08 ±
a
b
Fig. 3 Calpeptin treatment increases Smn protein level in MNs. CD1
mouse MNs were isolated and cultured in the presence of NTFs. a Six
days after plating, cells were treated with 25μMcalpeptin and cell lysates
obtained 3, 9, 16, 20, and 24 h after treatment. Protein extracts were
submitted to western blot analysis using an anti-SMN antibody.
Membranes were reprobed with an anti-α-tubulin antibody. Graph values
represent the expression of Smn vsα-tubulin and correspond to the quan-
tification of five independent experiments ± SEM. Asterisks indicate
significant differences using Student t test (*p < 0.05; **p < 0.005). b
Six days after plating, cells were treated with 30 K or 25 μM calpeptin
or 25 μM calpeptin+30K in the presence of NTFs. Three hours after
treatment, cell lysates were obtained and submitted to western blot using
anti-SMN or anti-α-fodrin antibodies. Membranes were reprobed with an
anti-α-tubulin antibody. Graph values represent the expression of Smn
(right) or 150/145 kDa fodrin product (left) vs α-tubulin and correspond
to the quantification of at least four independent experiments ± SEM.
Asterisks indicate significant differences using Student t test (*p < 0.05;
**p < 0.001; ***p < 0.0001)
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4.71%, p < 0.01) (data not shown). In order to analyze the
effect of calpain reduction on neurite degeneration, mutSMA
and WT cells were transduced with the lentivirus carrying
shCalp1 or EV constructs. After 6 days of transduction, no
significant differences were observed between groups.
However, 9 days after transduction, we detected a significant
difference in neurite morphology when the shCalp1 mutSMA
(16.64 ± 5.67%) was compared with the EV mutSMA (26.17
± 8.22%, p < 0.01) cultures. After 12 days, the signs of degen-
eration increased to 36.55 ± 2.28% in EV mutSMA cultures,
whereas shCalp1 mutSMA cultures showed significantly re-
duced degeneration (29.24 ± 4.89%, p < 0.0005), compared to
the EV mutSMA control (Fig. 5b). This percentage did not
differ from those observed in EV WT (26.29 ± 4.69%) and
shCalp1 WT (25.62 ± 3.61%). All these results together dem-
onstrate that calpain regulates Smn protein level and neurite
degeneration in Smn-reduced MNs.
Calpeptin Administration Extends Survival of Severe
SMA and SMNdelta7 SMA Mice
The evidences suggested that calpain regulates Smn protein
level positively in MNs. Therefore, we decided to examine
whether calpeptin administration had a positive effect on
SMA mice. To further assess this hypothesis, we started a
treatment protocol using two different SMA mouse models:
the FVB·Cg-Tg (SMN2)89AhmbSmn1tm1Msd/J (mutSMA)
and the FVB.Cg-Grm7Tg(SMN2)89Ahmb Smn1tm1Msd Tg
(SMN2*delta7)4299Ahmb/J (SMNdelta7). To determine if
calpeptin affected the lifespan and the body weight of these
mice, animals were tattooed and genotyped at postnatal day 0
(P0). WT and mutants littermates were grouped by sham or
treatment and the subcutaneous injections were started at P1,
with a daily dose of 6μg calpeptin per gram of weight. Results
showed that calpeptin administration significantly improved
lifespan of the mutSMA-calpeptin group (average days 9 ±
2.97, n = 11), compared with the mutSMA-sham (average
days 4.08 ± 2.54, n = 12, p < 0.0001) (Fig. 6a). Likewise,
lifespan of SMNdelta7-calpeptin group (average days 14.41
± 2.90, n = 15) was significantly increased compared to
SMNdelta7-sham (average days 9.8 ± 2.89, n = 10,
p < 0.0001) mice (Fig. 6b).
When the weight of the animal groups was measured, we
did not find significant differences in calpeptin-treated mutant
compared to non-treated mice. In contrast, weight was slightly
increased in calpeptin-treated WT groups compared with
sham-treated WT groups from day 13 of treatment to the
end of the experiment (Fig. 6c, d).
Fig. 4 Effect of high K+ and calpeptin treatment on SMN cleavage. CD1
MNs were cultured in the presence of NTFs. Six days after plating, cells
were treated with 30 mM KCl (30K) or 25 μM calpeptin or 30K plus
25 μM calpeptin. Three hours later, cell lysates were obtained and sub-
mitted to western blot using an anti-SMN (full length) or anti-SMN1 (C-
terminal fragments) antibodies. Membranes were reprobed with an anti-
α-tubulin antibody. Graph values represent the expression of full-length
Smn (left) or C-terminal Smn fragments (right) vs α-tubulin and corre-
spond to the quantification of at least three independent experiments ±
SEM. Asterisks indicate significant differences using Student t test
(*p < 0.05; **p < 0.005; ***p < 0.0001)
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Effect of Calpeptin Treatment on Motor Function
in SMA Mice
Because mutSMA and SMNdelta7 mouse models are charac-
terized by severe motor function impairment, we analyzed
whether the enhancement in lifespan observed in both models
after calpeptin treatment was correlated with motor functional
improvement. Two behavior tests were performed: the
righting reflex test and the tube test [32, 36]. The righting
reflex response is based on the ability of neonatal mice to
return to their four paws after having been placed in supine
position. It can be measured in pups as early as P1-P2 and
evaluated until P9-P10. The test was performed on mice in the
sham- or calpeptin-treated WT and sham- or calpeptin-treated
mutant (mutSMA and SMNdelta7) groups. The test was de-
signed with a maximum time of 30 s and measurements were
taken daily before the calpeptin injection from P1 to P10, done
in triplicate for each animal with 5 min resting time between
tests. Results obtained in WT groups showed that the righting
reflex time was consistently faster (~ 10 s) than in mutant
groups (~ 30 s). In calpeptin-treated mutSMA, there were no
significant differences from the beginning of the treatment
(P1) to P7 compared to sham-treated mutSMA. However,
from P7 to the end of the experiment the righting reflex time
progressively decreased in calpeptin-treated mutSMA and
SMNdelta7 (~ 20 s) (Fig. 7a, b).
The tube test is a non-invasive motor function test specif-
ically designed for neonatal rodents. It evaluates the proximal
a
b
Fig. 5 Calpeptin treatment increments Smn protein level and prevents
neurite degeneration in SMA MNs. E12.5 isolated MNs from WT and
mutSMA mice were cultured in the presence of NTFs. a Six days after
plating, cells were treated with 25 μM calpeptin or left untreated. Three
hours later, protein extracts were obtained and submitted to western blot
analysis using an anti-SMN antibody. Membranes were reprobed with an
anti-α-tubulin antibody. Graph values represent the expression of Smn vs
α-tubulin in WT and mutSMA (left and right) and correspond to the
quantification of three independent experiments ± SEM. Asterisks indi-
cate significant differences using Student t test (*p < 0.05). b Low-density
MN cultures of WT and mutSMA mice were established in the presence
of NTFs and transduced with lentivirus containing the shCalp1 construct
or the empty vector (EV) construct. Representative images of cells cul-
tured for 9 days after transduction. Arrows indicate neurite degeneration.
Scale bar 12 μm. The percentage of degenerating neurites was measured
as described in BMaterial and Methods.^ Graph values are the mean
number of degenerating neurites per microscopic area for each condition
of 12 wells in four independent experiments ± SEM. Asterisks indicate
significant differences using two-way ANOVA test and Bonferroni post-
test (*p < 0.01; ** p < 0.0005)
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hind-limb muscle strength, weakness, and fatigue. The animal
age range for this test is from P2 to P8. Two parameters were
evaluated in the present study: latency to fall from the edge of
the tube (in seconds, latency to fall graphs) and the hind-limb
score (HLS graphs) which assess the positioning of the legs
and tail. Mice with motor weakness show reduced time to fall
and low score of HLS. The test was performed in the same
sham and treated groups of mice described. The test was de-
signed with a maximum time of 30 s, and measures were
performed in triplicate daily before the calpeptin injection
from P1 to P8. When the latency time was analyzed in the
mutSMA model, we observed no differences in time-to-fall
from P1 to P5. Nevertheless, on days 6 (P6) and 7 (P7) after
treatment, calpeptin-treated mutSMA mice (P6, 15.62 ±
10.66 s, n = 7) showed significantly increased time-to-fall
compared to sham-treated mutSMA group (P6, 3.84 ± 1.92,
n = 3, p < 0.05) and no significant differences compared to
WT groups (P6 WT-SHAM, 19.4 ± 9.5) (Fig. 7c). In mutant
SMNdelta7 mice, calpeptin treatment significantly increased
latency-to-fall compared to sham-treated controls from P3 to
the end of the experiment (p < 0.05) (Fig. 7d). In both SMA
models, HLS measures revealed that calpeptin treatment of
mutant mice significantly increased the score compared to
sham mutants (mutSMA P2 to P8, p < 0.001; SMNdelta7 P6
to P8, p < 0.05) (Fig. 7e, f). Altogether, the results obtained
from the behavior tests suggested that calpeptin treatment
ameliorates motor function of mutant mice in both SMA
models analyzed.
Discussion
In the present study, calpain regulated Smn protein level in a
primary culture of isolated CD1 and Smn-reduced mice spinal
cord MNs. Calpain 1 knockdown or calpeptin treatment in-
creased Smn in these cells. Subcutaneous administration of
the calpain inhibitor, calpeptin, improved the survival and
phenotype of severe and SMNdelta7 SMAmice. In agreement
with previous publications demonstrating that Smn located in
the muscle cell is a proteolytic target of calpain [24, 25], we
showed here that Smn protein level in MNs can be modulated
by calpain. However, the functional implications of this
a b
c d
Fig. 6 Calpeptin administration extends survival of severe SMA and
SMNdelta7 SMA mice. a Survival of mutSMA treated with calpeptin.
b Survival of SMNdelta7 treated with calpeptin. The difference in
survival between calpeptin-treated mutSMA and SMNdelta7 mice and
non-treated was calculated by the log-rank Mantel-Cox test
(p < 0.0001). Weight gain of mutSMA (c) and SMNdelta7 (d) mice treat-
ed with calpeptin. Error bars indicate SEM
Mol Neurobiol
cleavage are not completely understood in the muscle cells
and neurons. SMN protein can be processed by caspases and
calpain. It has been previously reported that SMN calpain
cleavage sites are distinct from caspase sites. Apoptosis activ-
ity produces an N-terminal SMN product [37], whereas west-
ern analysis of calpain assays detects two SMN cleavage prod-
ucts (N- and C-terminus) [25]. In our MN culture system,
membrane depolarization treatment clearly increased C-
terminal Smn level, which is prevented by calpain inhibition.
One of the options to explain the importance of SMN cleavage
in the cellular function can be related to the role of the proteo-
lytic isoforms in cytoskeletal dynamics. In this context, many
evidences establish the importance of actin cytoskeletal dy-
namics in SMN function and SMA pathology [38]. Moreover,
it has been described that the C-terminal domain of SMN can
regulate the G- to F-actin ratio, and the expression of this
terminal fragment can rescue neurite outgrowth defects in
PC12 cells that have been depleted of endogenous Smn [39].
In cultured CD1 MNs, we have observed that calpeptin treat-
ment reduces Smn C-terminal fragment and increases full-
length Smn, indicating that calpain basal activity may process
Smn and regulate its level in these cells. Together, the muscle
and MN results strongly suggest a significant role of calpain
activity in SMN protein level control and SMA. Calpain is a
a b
c d
e f
Fig. 7 Calpeptin treatment improves motor function in SMAmice. Mean
time to right ± SEM between P1 and P10 measured in mutSMA groups
(a) or SMNdelta7 groups (b) Two-way ANOVA test and Bonferroni
posttest were performed to compare calpeptin-treated and untreated
groups. Asterisks indicate significant differences (*p < 0.05; **
p < 0.01; *** p < 0.0001). Mean of latency to fall ± SEM between P2
and P8 was measured in mutSMA groups (c) and SMNdelta7 groups (d),
and mean of hind-limb score ± SEM between P2 and P8 was measured in
mutSMA groups (e) and SMNdelta7 groups (f). Two-way ANOVA test
and Bonferroni posttest was performed to compare calpeptin-treated and
untreated groups. Asterisks indicate significant differences (*p < 0.05; **
p < 0.01; *** p < 0.001)
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regulatory protease, whose action typically activates or inac-
tivates a given protein target. Its activity is compartmentalized
and works in microenvironments where calcium can be con-
trolled [18]. In this context, it can be postulated that calcium
changes localized in the axonal compartment described in
SMA [40, 41] may contribute to the deregulation of calpain
activation and SMN processing.
The calcium/calpain pathway also controls the autophagy
process, which can be regulated by changes in intracellular
calcium level. It has been reported that pharmacological inhi-
bition of calpain or its genetic knockdown increases autopha-
gic flux without perturbing mTORC1 [42]. Pharmacological
release of calcium from intracellular stores blocks autophagic
flux, thereby increasing the number of autophagosomes, and
retards autophagic cargo clearance. In contrast, influx of ex-
tracellular calcium through L-type calcium channel agonists
inhibits autophagy at the level of autophagosome synthesis
[43]. Autophagy has been suggested as a fundamental process
whose dysregulation can be involved in neurodegenerative
disorders and might provide a potential target for therapy. In
fact, SMA mice treated with the autophagy inhibitor 3-
methyladenine showed delayed MN degeneration, improved
motor behavior, and increased lifespan of SMA [44] and the
neuroprotective effects of TTC (non-toxic carboxy-terminal
fragment of tetanus toxin heavy chain) treatment in SMAmice
are related to the reduced expression of autophagy markers
[45]. Previous results in cultured MNs, reported in
Periyakaruppiah et al. (2016), show that shCalp1 treatment
increased the level of LC3 II, suggesting that the endogenous
reduction of calpain increases autophagosome number. These
results are in accordance with previous reports that overex-
pression of consti tutively active calpain inhibits
autophagosome synthesis and that calpeptin treatment in-
creases the number of autophagosome-like structures and de-
creases the number of mitochondria (which are endogenous
autophagy substrates) in COS-7 cells [42]. In the present
study, calpeptin treatment ameliorates survival and phenotype
in two SMAmouse models. These observations, together with
the autophagy deregulation observed in SMN-reduced cells
[15, 16, 46], support the hypothesis that autophagy manipula-
tion may be useful in treating SMA, always keeping in mind
the complexity of the autophagy process and avoiding to at-
tribute the results obtained exclusively to autophagy regula-
tion. In this context, future studies focused on the role of
proteins involved in autophagy and other intracellular SMA-
altered mechanisms are needed to identify potential targets for
combinatorial therapeutics. Several mechanisms have positive
effects on SMA phenotype and should be regarded as candi-
dates for these combinatorial approaches, including autopha-
gy pathway modulators such as the autophagy inhibitor 3-
methyladenine [44] or the inhibition of the autophagy adaptor
p62 [47], butyrate-based compounds and other inhibitors of
histone deacetylase activity [11], and regulators of the
calcium-dependent acting-bundling protein Plastin-3 [48].
Other regulatory mechanisms involved in the degradation of
SMN, such as the ubiquitin-proteasome system, also warrant
analysis. The inhibition of both proteasome and calpain may
contribute to our understanding of these pathways to SMN
protein degradation.
Calpain inhibition or reduction clearly regulates Smn level
in MNs, prevents neurite degeneration, and improves survival
and phenotype of SMA mice models. However, calpeptin
treatment does not completely reverse the disease phenotype
observed in these mice. SMA disease complexity is likely
related to several functions of SMN which give rise to the
complete SMA pathology. For example, the molecular contri-
bution of SMN reduction in muscle and satellite cells of skel-
etal muscle on SMA phenotype remains unclear. It is known
that calpain regulates the level of SMN in this tissue; conse-
quently, it may be suggested that calpeptin treatment would
also ameliorate SMA phenotype due to increased SMN in
these cells. Nevertheless, further histopathologic analysis of
skeletal muscle would help to clarify this hypothesis.
SMA therapeutic approaches are designed as BSMN
dependent,^ contributing to increased SMN levels or BSMN
independent,^ which enhance the SMN-associated functions
or compensate for a secondary defect. We provide here a
BSMN dependent^ target for SMA therapeutics: calpain inhi-
bition. Our in vitro experiments showed that calpeptin treat-
ment or calpain 1 knockdown can increase SMN protein in
MNs. This effect is achieved by inhibiting calpain and increas-
ing SMN protein stability in these cells. Moreover, prelimi-
nary data using spinal cord protein extracts from calpeptin-
treated wild-type and mutant delta7 mice suggest an increase
in Smn, compared to controls (data not shown). In the context
of our ongoing research, we propose that quantification of
calpain expression and activity in SMA human tissue would
be of value for understanding the involvement of this protease
in SMN-reduced MN degeneration.
Calpain activation has been implicated in several neurolog-
ical diseases, including amyotrophic lateral sclerosis,
Alzheimer disease, Parkinson disease, stroke, and brain trau-
ma. Inhibitors of calpain have possible therapeutic applica-
tions to a range of disorders with neuronal cell loss. For ex-
ample, calpain inhibition is beneficial to the ALS phenotype
[49] and several clinical trials are underway with compounds
that inhibit calpain in Alzheimer disease [50]. Some authors
suggest a possible common neurodegenerative mechanism
shared by several adult onset brain disorders. Here, we dem-
onstrated that calpain inhibition is also beneficial in amelio-
rating a childhood-onset disease, which focuses the relevance
of calpain activity as an essential mechanism regulating neu-
rodegeneration in diseases of different origin.
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